Filgrastim
Brand names: Releuko · Active ingredient: Filgrastim
In short: RELEUKO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever . RELEUKO is indicated for reducing the ti
What is Filgrastim used for?
RELEUKO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever .
RELEUKO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) .
RELEUKO is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation .
RELEUKO is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis .
RELEUKO is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia .
RELEUKO is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation .
Filgrastim dosage
The recommended starting dosage of RELEUKO is 5 mcg/kg/day‚ administered as a single daily injection by subcutaneous injection‚ by short intravenous infusion (15 to 30 minutes)‚ or by continuous intravenous infusion. Obtain a complete blood count (CBC) and platelet count before instituting RELEUKO therapy and monitor twice weekly during therapy. Consider dose escalation in increments of 5 mcg/kg for each chemotherapy cycle‚ according to the duration and severity of the absolute neutrophil count (ANC) nadir. Recommend stopping RELEUKO if the ANC increases beyond 10‚000/mm3
.
Administer RELEUKO at least 24 hours after chemotherapy. Do not administer RELEUKO within the 24- hour period prior to chemotherapy . A transient increase in neutrophil count is typically seen 1 to 2 days after initiation of RELEUKO therapy. Therefore, to ensure a sustained therapeutic response, administer RELEUKO daily for up to 2 weeks or until the ANC has reached 10‚000/mm3 following the expected chemotherapy-induced neutrophil nadir. The duration of RELEUKO therapy needed to attenuate chemotherapy-induced neutropenia may be dependent on the myelosuppressive potential of the chemotherapy
regimen employed.
The recommended dosage of RELEUKO following bone marrow transplantation (BMT) is 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. Administer the first dose of RELEUKO at least 24 hours after chemotherapy and at least 24 hours after bone marrow infusion. Monitor CBCs and platelet counts frequently following marrow transplantation.
During the period of neutrophil recovery‚ titrate the daily dosage of RELEUKO against the neutrophil response .
Absolute Neutrophil Count | RELEUKO Dosage Adjustment
When ANC greater than 1,000/mm3 for 3 consecutive days | Reduce to 5 mcg/kg/daya
Then, if ANC remains greater than 1,000/mm3
for 3 more consecutive days | Discontinue RELEUKO
Then, if ANC decreases to less than 1,000/mm3 | Resume at 5 mcg/kg/day
a If ANC decreases to less than 1,000/mm3 at any time during the 5 mcg/kg/day administration‚ increase RELEUKO to 10 mcg/kg/day‚ and then follow the above steps.
The recommended dosage of RELEUKO for the mobilization of autologous peripheral blood progenitor cells (PBPC) is 10 mcg/kg/day given by subcutaneous injection. Administer RELEUKO for at least 4 days before the first leukapheresis procedure and continue until the last leukapheresis. Although the optimal duration of RELEUKO administration and leukapheresis schedule have not been established‚ administration of filgrastim for 6 to 7 days with leukaphereses on days 5‚ 6‚ and 7 was found to be safe and effective . Monitor neutrophil counts after 4 days of RELEUKO‚ and discontinue RELEUKO if the white blood cell (WBC) count rises to greater than 100‚000/mm3. …
How to take Filgrastim — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Review the steps for direct patient administration with patients and caregivers. Training by the healthcare provider
should aim to ensure that patients and caregivers can successfully perform all of the steps in the Instructions for Use
of RELEUKO vial and prefilled syringe, including showing the patient or caregiver how to measure the required
dose, particularly if a patient is on a dose other than the entire prefilled syringe. If a patient or caregiver is not able to
demonstrate that they can measure the dose and administer the product successfully, you should consider whether
the patient is an appropriate candidate for self-administration of RELEUKO or whether the patient would benefit
from a different RELEUKO presentation.
Advise patients of the following risks and potential risks with RELEUKO:
Rupture or enlargement of the spleen may occur. Symptoms include left upper quadrant abdominal pain or left shoulder pain. Advise patients to report pain in these areas to their physician immediately . …
Warnings & precautions
Do not take this medicine if: RELEUKO is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products .
Splenic rupture, including fatal cases, has been reported following the administration of filgrastim products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
Acute respiratory distress syndrome (ARDS) has been reported in patients receiving filgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue RELEUKO in patients with ARDS.
Serious allergic reactions, including anaphylaxis, have been reported in patients receiving filgrastim products. The majority of reported events occurred upon initial exposure. Provide symptomatic treatment for allergic reactions. Allergic reactions, including anaphylaxis, in patients receiving filgrastim products can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue RELEUKO in patients with serious allergic reactions. RELEUKO is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products.
Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim products. Discontinue RELEUKO if sickle cell crisis occurs.
Glomerulonephritis has occurred in patients receiving filgrastim products. The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of filgrastim products. If glomerulonephritis is suspected, evaluate for cause. …
Filgrastim side effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
Splenic Rupture
Acute Respiratory Distress Syndrome
Serious Allergic Reactions
Sickle Cell Disorders
Glomerulonephritis
Alveolar Hemorrhage and Hemoptysis
Capillary Leak Syndrome
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Thrombocytopenia
Leukocytosis
Cutaneous Vasculitis
Large and Medium Vessel Arteritis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions in Patients with Cancer Receiving Myelosuppressive Chemotherapy
The following adverse reaction data in Table 2 are from three randomized, placebo-controlled studies in patients with:
small cell lung cancer receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide (Study 1)
small cell lung cancer receiving ifosfamide, doxorubicin‚ and etoposide (Study 2), and
non-Hodgkin’s lymphoma (NHL) receiving doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, and methotrexate (“ACVBP”) or mitoxantrone, ifosfamide, mitoguazone, teniposide, methotrexate, folinic acid, methylprednisolone, and methotrexate (“VIM3”) (Study 3). …
About this medicine
Filgrastim-ayow, a leukocyte growth factor, is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology. Filgrastim-ayow is produced by Escherichia coli (E. coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. Filgrastim-ayow has a molecular weight of 18‚800 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E. coli. Because filgrastim-ayow is produced in E. coli‚ the product is non-glycosylated and thus differs from G-CSF isolated from a human cell. Kanamycin, 50 mcg/mL is final concentration, is used during the fermentation step of the manufacturing process. Kanamycin is not detectable in the final product.
RELEUKO (filgrastim-ayow) injection is a sterile‚ clear‚ colorless‚ preservative-free liquid containing filgrastim-ayow at a specific activity of 1.0 ± 0.6 x 108 U/mg (as measured by a cell mitogenesis assay). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 74e1ec6e-1630-4654-895c-2bd355f939e7. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate